Eagle Pharmaceuticals, Inc. (EGRX)
USD 1.96
(30.67%)
USD 1.96
(30.67%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 | 35.64 Million USD | 513.14% |
| 2021 | -8.62 Million USD | -171.96% |
| 2020 | 11.98 Million USD | -16.24% |
| 2019 | 14.31 Million USD | -55.14% |
| 2018 | 31.9 Million USD | -38.58% |
| 2017 | 51.94 Million USD | -36.23% |
| 2016 | 81.45 Million USD | 3068.14% |
| 2015 | 2.57 Million USD | 114.3% |
| 2014 | -17.97 Million USD | -197.22% |
| 2013 | -6.04 Million USD | 68.79% |
| 2012 | -19.38 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q2 | 5.16 Million USD | -10.19% |
| 2023 Q1 | 5.75 Million USD | -29.58% |
| 2022 Q1 | 44.05 Million USD | 811.07% |
| 2022 FY | 35.64 Million USD | 513.14% |
| 2022 Q2 | -9.45 Million USD | -121.45% |
| 2022 Q3 | -3.51 Million USD | 62.83% |
| 2022 Q4 | 8.16 Million USD | 332.42% |
| 2021 FY | -8.62 Million USD | -171.96% |
| 2021 Q3 | -5.62 Million USD | -255.65% |
| 2021 Q4 | -6.19 Million USD | -10.21% |
| 2021 Q2 | 3.61 Million USD | 957.96% |
| 2021 Q1 | -421 Thousand USD | -105.23% |
| 2020 Q3 | 7.05 Million USD | 2857.42% |
| 2020 Q1 | -2.87 Million USD | -385.67% |
| 2020 Q2 | -256 Thousand USD | 91.08% |
| 2020 Q4 | 8.05 Million USD | 14.14% |
| 2020 FY | 11.98 Million USD | -16.24% |
| 2019 Q2 | 6.72 Million USD | -25.05% |
| 2019 Q4 | 1 Million USD | 142.05% |
| 2019 Q3 | -2.39 Million USD | -135.54% |
| 2019 FY | 14.31 Million USD | -55.14% |
| 2019 Q1 | 8.97 Million USD | -28.73% |
| 2018 Q3 | 14.04 Million USD | 428.02% |
| 2018 Q2 | 2.65 Million USD | 1.64% |
| 2018 Q1 | 2.61 Million USD | -71.21% |
| 2018 FY | 31.9 Million USD | -38.58% |
| 2018 Q4 | 12.59 Million USD | -10.33% |
| 2017 Q4 | 9.08 Million USD | -41.13% |
| 2017 Q2 | 4.5 Million USD | -80.36% |
| 2017 Q1 | 22.92 Million USD | -59.99% |
| 2017 FY | 51.94 Million USD | -36.23% |
| 2017 Q3 | 15.43 Million USD | 242.68% |
| 2016 Q1 | -896 Thousand USD | -173.5% |
| 2016 Q4 | 57.3 Million USD | 379.43% |
| 2016 Q3 | 11.95 Million USD | -8.76% |
| 2016 Q2 | 13.09 Million USD | 1561.94% |
| 2016 FY | 81.45 Million USD | 3068.14% |
| 2015 Q4 | 1.21 Million USD | 111.99% |
| 2015 FY | 2.57 Million USD | 114.3% |
| 2015 Q3 | -10.16 Million USD | -24.34% |
| 2015 Q2 | -8.17 Million USD | -141.51% |
| 2015 Q1 | 19.69 Million USD | 457.74% |
| 2014 Q3 | -9.1 Million USD | -210.28% |
| 2014 FY | -17.97 Million USD | -197.22% |
| 2014 Q4 | -5.5 Million USD | 39.52% |
| 2014 Q2 | -2.93 Million USD | -9.3% |
| 2014 Q1 | -2.68 Million USD | 17.54% |
| 2013 Q2 | 754.57 Thousand USD | 115.71% |
| 2013 Q1 | -4.8 Million USD | -93.51% |
| 2013 Q3 | 483.32 Thousand USD | -35.95% |
| 2013 FY | -6.04 Million USD | 68.79% |
| 2013 Q4 | -3.25 Million USD | -773.48% |
| 2012 Q3 | -5.19 Million USD | 0.0% |
| 2012 Q4 | -2.48 Million USD | 52.23% |
| 2012 FY | -19.38 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bright Green Corporation | -13.12 Million USD | 371.503% |
| BioQuest Corp. | -123.33 USD | 28899799.992% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | 299.128% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | -22453.517% |
| GSRX Industries Inc. | - USD | -Infinity% |
| High Sierra Technologies, Inc. | -323.95 Thousand USD | 11102.247% |
| Instadose Pharma Corp. | - USD | -Infinity% |